Pages that link to "Q74620971"
Jump to navigation
Jump to search
The following pages link to The use of lofexidine by drug dependency units in the United Kingdom (Q74620971):
Displaying 14 items.
- Alpha2-adrenergic agonists for the management of opioid withdrawal (Q24185795) (← links)
- Alpha2-adrenergic agonists for the management of opioid withdrawal (Q24197769) (← links)
- Alpha 2 -adrenergic agonists for the management of opioid withdrawal (Q24241305) (← links)
- Alpha2 adrenergic agonists for the management of opioid withdrawal (Q24245988) (← links)
- Inpatient versus other settings for detoxification for opioid dependence (Q24247002) (← links)
- Acceptability and availability of harm-reduction interventions for drug abuse in American substance abuse treatment agencies (Q30335760) (← links)
- Evidence-based addiction medicine: the use of lofexidine for opioid detoxification (Q34444149) (← links)
- Electrocardiographic effects of lofexidine and methadone coadministration: secondary findings from a safety study. (Q35147971) (← links)
- A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal (Q37036723) (← links)
- Lofexidine versus clonidine in rapid opiate detoxification (Q43715663) (← links)
- Two methods of community detoxification from opiates: an open-label comparison of lofexidine and buprenorphine (Q43803507) (← links)
- Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone (Q44049012) (← links)
- A placebo-controlled study of lofexidine in the treatment of children with tic disorders and attention deficit hyperactivity disorder (Q44393742) (← links)
- Lofexidine in opiate withdrawal: a safety and usage survey (Q82690995) (← links)